Disease Domain | Count |
---|---|
Infectious Diseases | 4 |
Neoplasms | 1 |
Top 5 Drug Type | Count |
---|---|
Small molecule drug | 4 |
Diagnostic radiopharmaceuticals | 1 |
Target- |
Mechanism PET imaging |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhasePhase 3 |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target- |
Mechanism- |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhasePreclinical |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target- |
Mechanism- |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhasePreclinical |
First Approval Ctry. / Loc.- |
First Approval Date- |
Start Date01 Nov 2024 |
Sponsor / Collaborator |
Start Date11 Sep 2024 |
Sponsor / Collaborator |
Start Date01 Sep 2024 |
Sponsor / Collaborator |
Drug(Targets) | Indications | Global Highest Phase |
---|---|---|
[18F]PSMA-PET | Prostatic Cancer More | Phase 3 |
Benzavir-2 | Herpes Simplex More | Preclinical |
Benzavir-1 | Herpes Simplex More | Preclinical |
C-10 | Tuberculosis More | Preclinical |
17j | Tuberculosis More | Preclinical |